Technical Analysis for HNCMF - Hutchison China Meditech

Grade Last Price % Change Price Change
grade B 61.6 0.82% 0.5000
HNCMF closed up 0.82 percent on Thursday, April 4, 2019, on 2.23 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A N/A
See historical HNCMF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%

Older signals for HNCMF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Medicine RTT Cancer Pharmaceuticals Clinical Medicine Biopharmaceutical Chemical Compounds Disease Healthcare Products Autoimmune Diseases Solid Tumors Rheumatoid Arthritis Antineoplastic Drugs Ulcerative Colitis Non Small Cell Lung Cancer Glioblastoma Over The Counter Pharmaceutical Products Targeted Therapy Consumer Health Products Crohn's Non Small Cell Lung Carcinoma Treatment Of Non Small Cell Lung Cancer Esophageal Cancer Gastric Cancer Hematologic Cancers Neuroendocrine Tumors Pyrazoles Ros1
Is HNCMF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 61.9542
52 Week Low 61.1
Average Volume 1,566
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 61.6000
Resistance 3 (R3) 61.6000 61.6000 61.6000
Resistance 2 (R2) 61.6000 61.6000 61.6000 61.6000
Resistance 1 (R1) 61.6000 61.6000 61.6000 61.6000 61.6000
Pivot Point 61.6000 61.6000 61.6000 61.6000 61.6000
Support 1 (S1) 61.6000 61.6000 61.6000 61.6000 61.6000
Support 2 (S2) 61.6000 61.6000 61.6000 61.6000
Support 3 (S3) 61.6000 61.6000 61.6000
Support 4 (S4) 61.6000